In the days of the Armada, a fleet of warships, the scuttlebutt was the rumor or gossip that would spread throughout the ship. Today, Armada Law Corp presents The Scuttlebutt, a daily summery of news articles that people within the cannabis, hemp and plant medicine industries are chatting about along with links to the full articles.
In today’s news:
#psilocybin – “In 2020, Oregon made history when voters passed Measure 109, which would legalize the medical use of psilocybin under the care of a licensed facilitator. It passed with 56% of the vote.
Yet this November, exactly two years later, residents of two-thirds of Oregon’s 36 counties will vote to ban psilocybin therapeutic centers, or implement a two-year moratorium on those services. Local governments retain the power to put such a vote on the ballot.
None of the state’s ten largest cities will vote to opt out. That means psilocybin therapeutic centers will be allowed in cities like Portland, Eugene, Salem, and Bend.”
#hempderivedproducts – “Analyses indicated that of the 53 samples examined, 49 were incorrectly labeled as hemp because they technically fit the federal classification of marijuana (Figure 2). Of the 34 “hemp” samples obtained from Vendor 1, only two fit the federal classification of hemp as determined by total THC; the remaining 32 samples fit the federal classification of marijuana. Of the eight samples from Vendors 2 and 3, none of the “hemp” samples examined should be classified as hemp—all should technically be marijuana. And of the 11 “hemp” samples examined from Vendors 4 and 5, only two samples fit the federal classification for hemp, while nine were technically marijuana. Of the inaccurately labeled samples, virtually all had total THC concentrations under 1 percent but above the legal threshold of 0.3 percent.”
#psychedelics – “Now, medical researchers are exploring ways to harness magic mushrooms and other psychedelic substances to help treat mental health conditions like depression, addiction, and PTSD—sometimes with dramatic results. But what actually happens in the brain during a psychedelic experience? Fred Barrett, a neuroscientist at Johns Hopkins University, is one of the scientists trying to figure that out. His work suggests that “a brain region called the claustrum may be at the center of all of this,” he told NOVA.”
#productliability – “As a society, we hold product manufacturers liable for placing an unreasonably dangerous product on the market. What is “unreasonably dangerous,” however, is an open question when it comes to cannabis since, until recently, federal illegality largely precluded the availability of reliable studies on questions of safety and efficacy. The number and quality of such studies have increased over the past few years, coinciding with cannabis legalization at the state level, relaxation of rules around cannabis research and removal of hemp from the Controlled Substances Act (CSA).
Armed with these new studies, potential plaintiffs may start seeking to use the courts as quasi-regulators for the cannabis and hemp industries. Some lawsuits already have alleged, for example, that cannabis companies seek to take advantage of the public’s perception of cannabis products as safe and healthy despite the fact that THC and other cannabinoids have been linked to various adverse side effects. It also has been alleged that although edible cannabis products are linked to more severe adverse effects than smoking marijuana, those products have been marketed by some companies as the safer and healthier alternative. The hemp industry, meanwhile, should brace itself for similar allegations brought against hemp-derived THC products that are becoming increasingly popular and available.”